Clonal evolution and survival from time of new cytogenetic change
| Cytogenetics at reassessment . | n (%) . | Median survival, mo . |
|---|---|---|
| Remained diploid | 53 (73) | 36 |
| Favorable abnormalities | 5 (7) | 31 |
| Unfavorable abnormalities | 6 (8) | 18 |
| Abnormal chromosome 17 | 6 (8) | 9 |
| Other abnormalities | 3 (4) | 21 |
| Cytogenetics at reassessment . | n (%) . | Median survival, mo . |
|---|---|---|
| Remained diploid | 53 (73) | 36 |
| Favorable abnormalities | 5 (7) | 31 |
| Unfavorable abnormalities | 6 (8) | 18 |
| Abnormal chromosome 17 | 6 (8) | 9 |
| Other abnormalities | 3 (4) | 21 |
Patients who had repeat cytogenetics testing performed for progressive disease or blast phase transformation were excluded from this analysis. Patients who had more than 1 repeat cytogenetics testing during follow-up were classified according to the last marrow examination to show karyotypic progression.